FY2025 Earnings Forecast for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at B. Riley cut their FY2025 EPS estimates for shares of Cytokinetics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($5.65) per share for the year, down from their previous forecast of ($5.30). The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics' FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($2.37) EPS.

Other analysts also recently issued reports about the stock. Needham & Company LLC restated a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a research report on Thursday, February 6th. Stifel Nicolaus initiated coverage on Cytokinetics in a research note on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 price objective for the company. Citigroup initiated coverage on Cytokinetics in a research note on Friday, February 7th. They issued a "buy" rating and a $86.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a report on Friday, February 28th. Finally, Morgan Stanley set a $67.00 target price on shares of Cytokinetics in a report on Friday. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $82.00.

Remove Ads

Cytokinetics Stock Performance

Shares of CYTK stock traded up $1.09 during trading hours on Friday, reaching $44.40. 1,967,343 shares of the company traded hands, compared to its average volume of 1,575,645. The firm has a 50-day moving average price of $46.65 and a 200 day moving average price of $50.66. The company has a market cap of $5.26 billion, a P/E ratio of -8.25 and a beta of 0.95. Cytokinetics has a 12-month low of $40.53 and a 12-month high of $75.71. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million.

Hedge Funds Weigh In On Cytokinetics

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of Cytokinetics during the fourth quarter worth $117,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in Cytokinetics in the 4th quarter worth about $15,483,000. Vestal Point Capital LP increased its stake in Cytokinetics by 56.7% in the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company's stock worth $110,544,000 after buying an additional 850,000 shares during the period. Two Sigma Advisers LP lifted its holdings in Cytokinetics by 5.4% during the 4th quarter. Two Sigma Advisers LP now owns 226,400 shares of the biopharmaceutical company's stock valued at $10,650,000 after buying an additional 11,700 shares in the last quarter. Finally, Teza Capital Management LLC purchased a new stake in Cytokinetics in the 4th quarter valued at about $446,000.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 3,341 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. The trade was a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total value of $98,640.00. Following the completion of the sale, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,724,621.72. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,833 shares of company stock worth $1,386,118 over the last quarter. Insiders own 3.40% of the company's stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.